WRF
JUNO

Waddell & Reed Financial’s Juno Therapeutics, Inc. JUNO Stock Holding History

Waddell & Reed Financial’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-62,400
Closed -$3.26M – 608
2014
Q4 		$3.26M Buy
+62,400
New +$2.79M ﹤0.01% 515

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Waddell & Reed Financial's JUNO Position: Q1 2015 in Review

Waddell & Reed Financial sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2015, closing a stake of 62,400 shares — an estimated $3.26M sold.

Waddell & Reed Financial first reported a position in JUNO in Q4 2014 and held it in 1 quarter. The position peaked at $3.26M in Q4 2014. 120 funds tracked by Wall St. Rank hold JUNO as of Q1 2015.

  • Waddell & Reed Financial reported no remaining Juno Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Waddell & Reed Financial sold 62,400 Juno Therapeutics, Inc. shares in Q1 2015, an estimated $3.26M.
  • Waddell & Reed Financial first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
  • Waddell & Reed Financial's Juno Therapeutics, Inc. position peaked at $3.26M in Q4 2014.
  • 120 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2015.

Based on Waddell & Reed Financial's 13F filing for Q1 2015, filed 15 May 2015.